← Leaderboards
Jezabel Rodriguez-Blanco
Medical University Of South Carolina
$1,640,755
Attributed
$1,640,755
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $775.4K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,640,755 · 2
By mechanism
K01$1,081,725 · 1
R01$559,030 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Inderjit Singh$14,537,080
- Narayan R Bhat$5,057,283
- Arno Wessels$8,106,610
- Andy Y Shih$15,856,823
- Sophie Paczesny$15,189,813
Others in their field
Other Emerging Leaders on “Self-Renewal”
- Robert A.j. Signer · University Of California, San Diego$6,799,660
- Jeffrey Alan Magee · Washington University$5,414,962
- Maddalena Adorno · Dorian Therapeutics, Inc.$4,178,124
- Miyeko Mana · Arizona State University-Tempe Campus$4,123,049
- Antoine Elias Karnoub · Va Boston Health Care System$3,772,656
- Lauren Marie Sparks · Adventhealth Orlando$3,673,389
Research focus
Self-RenewalSubgroupPublishingRelapseSmall MoleculeStandard Of CareMedulloblastomaPathway InteractionsRecurrenceCancer EtiologyShh GeneSignal TransductionFutureSmoothened Signaling PathwayCellsGrowthMolecularMutationClassificationChildChildhood Brain NeoplasmChildhood Cancer MortalityDesignSuccess
Grant awards (6)
Uncovering the Signaling Mechanisms Underlying Treatment Failure in Medulloblastoma$559,030
R01 · FY2025 · NS · contact PI
Identifying Novel Therapeutics for High Risk Medulloblastoma Patients$216,345
K01 · FY2025 · NS · contact PI
Identifying Novel Therapeutics for High Risk Medulloblastoma Patients$216,345
K01 · FY2024 · NS · contact PI
Identifying Novel Therapeutics for High Risk Medulloblastoma Patients$216,345
K01 · FY2023 · NS · contact PI
Identifying Novel Therapeutics for High Risk Medulloblastoma Patients$216,345
K01 · FY2022 · NS · contact PI
Identifying Novel Therapeutics for High Risk Medulloblastoma Patients$216,345
K01 · FY2021 · NS · contact PI